Health Care • Medical/Dental Instruments
$23.51 ▼ -1.10
(-4.47%)
MKT CAP: $3.95B • VOL: 3.73M
52W L $19 52W H $30
NVST // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.72B | $2.51B | $2.57B |
| YoY Revenue Growth % | +8.3% | -2.2% | — |
| Gross Profit | $1.49B | $1.37B | — |
| Gross Margin % | 54.7% | 54.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $216.1M | -$1.04B | $31.5M |
| Operating Margin % | 7.9% | -41.4% | 1.2% |
| Net Income (GAAP) | $47.0M | -$1.12B | -$100.2M |
| EBITDA (Normalized) | $252.3M | -$1.01B | $123.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $275.7M | $336.5M | $275.7M |
| Capital Expenditures (CapEx) | $45.3M | $33.8M | $115.5M |
| Free Cash Flow (FCF) | $230.4M | $302.7M | $160.2M |
| FCF Margin % | 8.5% | 12.1% | 6.2% |
| Return on Invested Capital (ROIC %) | 5.1% | -26.1% | 1.3% |
| Cash & Short-Term Equivalents | $1.21B | $1.07B | — |
| Total Debt (Short + Long Term) | $1.45B | $1.28B | $720.7M |
| Total Stockholders' Equity | $3.11B | $2.93B | $1.48B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NVST.